In a phase I study in 33 patients with mBCC or laBCC, tumor GLI1 was overexpressed as compared with normal skin controls; skin biopsies showed that GLI1 expression was down-modulated more than 2-fold in 10 (77%) of 13 patients following treatment with vismodegib [24]. Here, GLI1 is linked to neoplasm.